Scholars@Duke
construction release_alert
Profile editing will be unavailable for Scholars@Duke profiles from June 11-24, 2026 as manual profile data entry transitions to Elements. More information about the transition.
cancel
Gretchen Genevieve Kimmick

Gretchen Genevieve Kimmick

Professor of Medicine
Medicine, Medical Oncology
gretchen.kimmick@duke.edu
Duke Box 3204, Durham, NC 27710
10 Bryan-Searle Drive, 441 Seeley G. Mudd Bldg, Durham, NC 27710

Selected Publications

Clinical and Demographic Characteristics of Patients With Long-Term Disease Control With First-Line Endocrine Therapy Alone for Hormone Receptor Positive, HER2 Negative, Metastatic Breast Cancer

Journal Article Clinical Breast Cancer · June 1, 2026 Purpose: To describe characteristics of patients with hormone receptor positive, HER2 negative, metastatic breast cancer (HR + MBC) who have long-term disease control with single-agent, first-line endocrine therapy (ET). Methods: Patients with HR + MBC sta ... Full text Cite

TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2.

Journal Article J Clin Oncol · March 10, 2026 PURPOSE: Translational Breast Cancer Research Consortium 048 was a proof-of-principle trial demonstrating responses to the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in patients (pts) with metastatic breast cancer (MBC) with germline (g) PALB2 ... Full text Link to item Cite

Receipt of guideline-concordant local and chemotherapy-based systemic therapy for patients with triple-negative breast cancer: 10-year survival outcomes in a multi-state population-based analysis.

Journal Article Cancer · February 15, 2026 BACKGROUND: Women diagnosed with triple-negative (ER-, PR-, HER2-) breast cancer (TNBC) have poor survival outcomes compared with other breast cancer subtypes. Yet there is little nonexperimental data on whether guideline-concordant therapy translates to b ... Full text Link to item Cite

Examining the Interrelationships of Lymphedema with Pain, Physical Function, and Demographic and Medical Variables in Women with Breast Cancer and Pain.

Journal Article Clin Breast Cancer · January 2026 PURPOSE: To examine the relationship of lymphedema with pain, physical function, and demographic and medical variables in women with breast cancer and pain. METHODS: Secondary analysis of baseline data from a study of women with breast cancer and pain. Sel ... Full text Link to item Cite

Abstract P2-10-05: Survival in Older Women Receiving Adjuvant Radiation Monotherapy vs. Endocrine Monotherapy Following Lumpectomy

Conference Clinical Cancer Research · June 13, 2025 AbstractBackground: Breast cancer is increasingly prevalent in women over 65, and most are diagnosed with hormone receptor positive disease. While younger patients with early-stage breast cancer are treated ... Full text Cite

Adjuvant Radiation vs Endocrine Therapy After Lumpectomy for Early-Stage Breast Cancer in Older Women: Analysis of Real-World Survival Outcomes.

Journal Article Ann Surg Oncol · June 6, 2025 BACKGROUND: We examined whether adjuvant radiation therapy (RT) monotherapy offers comparable overall survival (OS) to adjuvant endocrine therapy (ET) monotherapy following lumpectomy in women aged ≥ 65 years with favorable early stage breast cancer. PATIE ... Full text Link to item Cite

Disparities in treatment delays among metastatic breast cancer patients: insights from nationwide electronic health records, 2011-2022.

Journal Article Breast Cancer Res Treat · April 2025 PURPOSE: While previous research has highlighted treatment delay inequities in early-stage breast cancer and identified potential contributing factors, there is limited research on disparities in treatment delays for metastatic breast cancer (MBC). This st ... Full text Link to item Cite

Web-Based Pain Coping Skills Training (PCST) for Managing Aromatase Inhibitor-Associated Arthralgia in Breast Cancer Survivors: Randomized Controlled Trial Protocol.

Journal Article Contemp Clin Trials · February 2025 BACKGROUND: Aromatase inhibitors (AIs) are a cornerstone of adjuvant systemic therapy for postmenopausal patients with hormone-receptor positive (HR+) breast cancer. Although AIs decrease cancer recurrence rates and improve survival rates, approximately 50 ... Full text Link to item Cite

The Cost-Effectiveness of CDK4/6 Inhibitors in Treating HR+/HER2- Metastatic Breast Cancer Patients in the USA: When Non-medication Expenses are Considered.

Journal Article Clin Drug Investig · February 2025 BACKGROUND AND OBJECTIVE: Cyclin-dependent kinase (CDK)4/6 inhibitors in combination with endocrine therapy (ET) significantly enhance progression-free survival and overall survival in patients diagnosed with HR+/HER2- metastatic breast cancer (MBC). Howev ... Full text Link to item Cite

First- vs second-line CDK 4/6 inhibitor use for patients with hormone receptor positive, human epidermal growth-factor receptor-2 negative, metastatic breast cancer in the real world setting.

Journal Article Breast Cancer Res Treat · November 2024 PURPOSE: To compare CDK4/6 inhibitor (CDK4/6i) with endocrine therapy (ET) in the first- versus second-line setting for treatment of hormone receptor positive (HR+), HER2 negative, metastatic breast cancer (MBC) using real-world evidence. METHODS: Patients ... Full text Link to item Cite

Disparities in receipt of 1-st line CDK4/6 inhibitors with endocrine therapy for treatment of hormone receptor positive, HER2 negative metastatic breast cancer in the real-world setting.

Journal Article Breast Cancer Res · October 18, 2024 OBJECTIVE: This study used real-world observational data to compare profiles of patients receiving different first-line treatment for hormone receptor positive (ER+), HER2 negative, metastatic breast cancer (MBC): CDK4/6 inhibitors (CDK4/6i) in combination ... Full text Link to item Cite

Survival among patients with untreated metastatic breast cancer: "What if I do nothing?".

Journal Article Breast Cancer Res Treat · June 2024 PURPOSE: We sought to assess survival outcomes of patients with de novo metastatic breast cancer (dnMBC) who did not receive treatment irrespective of the reason. METHODS: Adults with dnMBC were selected from the NCDB (2010-2016) and stratified based on re ... Full text Link to item Cite

Unveiling the cost-effectiveness of CDK4/6 inhibitors in treating patients with HR+/HER2- metastatic breast cancer: A closer look at nonmedication expenses.

Conference Journal of Clinical Oncology · June 1, 2024 1532Background: Cyclin-dependent kinase (CDK)4/6 inhibitors have significantly enhanced survival outcomes in postmenopausal patients diagnosed with HR+ MBC. Their integration with endocrine therapy (ET) has become the standard of care in MBC treatment line ... Full text Cite

TBCRC 048 (olaparib expanded) expansion cohorts: Phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2.

Conference Journal of Clinical Oncology · June 1, 2024 1021Background: TBCRC 048 is an investigator-initiated proof of principle phase II trial that demonstrated responses with monotherapy olaparib in MBC pts with gPALB2 or sBRCA mutations. Here we report results of the expansion cohorts for additional pts wit ... Full text Cite

Anatomy Versus Biology: What Guides Chemotherapy Decisions in Older Patients With Breast Cancer?

Journal Article J Surg Res · April 2024 INTRODUCTION: With the increasing utilization of genomic assays, such as the Oncotype DX recurrence score (RS), the relevance of anatomic staging has been questioned for select older patients with breast cancer. We sought to evaluate differences in chemoth ... Full text Link to item Cite

Molecular profiling of serial liquid biopsy specimens utilizing cell free DNA (cfDNA) and circulating tumor cells (CTCs) in TBCRC041: A phase II study of alisertib in endocrine resistant metastatic breast cancer (MBC)

Conference Journal of Clinical Oncology · January 1, 2024 Background: TBCRC041, a randomized phase 2 trial of alisertib (A) 6 fulvestrant (F) in women with HR+/HER2- MBC demonstrated promising clinical activity for alisertib (1). Interrogation of baseline (PreC1) and end of cycle 1 (EOC1) cfDNA and CTCs may ident ... Full text Cite

Association of self-directed walking with toxicity moderation during chemotherapy for the treatment of early breast cancer.

Journal Article Support Care Cancer · December 28, 2023 BACKGROUND: In the field of exercise oncology, there is a need to quantify the potential benefits of moderate, self-directed physical activity during active treatment. In a pooled analysis of three identical single-arm intervention studies, we investigate ... Full text Open Access Link to item Cite

Behavioral cancer pain intervention dosing: results of a Sequential Multiple Assignment Randomized Trial.

Journal Article Pain · September 1, 2023 Behavioral pain management interventions are efficacious for reducing pain in patients with cancer. However, optimal dosing of behavioral pain interventions for pain reduction is unknown, and this hinders routine clinical use. A Sequential Multiple Assignm ... Full text Link to item Cite

Prognostic Tools for Older Women with Breast Cancer: A Systematic Review.

Journal Article Medicina (Kaunas) · August 30, 2023 Background: Breast cancer is the most common cancer in women, and older patients comprise an increasing proportion of patients with this disease. The older breast cancer population is heterogenous with unique factors affecting clinical decision making. Whi ... Full text Link to item Cite

The real-world modeling of benefits demonstrated in major clinical trials on 2 HR+/HER2− metastatic breast cancer treatment with CDK4/6 inhibitor in the US: PALOMA-2 and MONALEESA-3.

Conference Journal of Clinical Oncology · June 1, 2023 e13070 Background: This retrospective study addresses the question of whether real-world treatment with CDK4/6 inhibitors in combination with Endocrine Therapy (ET) for advanced hormone receptor positive (ER+) HER2 negative breas ... Full text Cite

Body mass index and patient-reported function, quality of life and treatment toxicity in women receiving adjuvant chemotherapy for breast cancer.

Journal Article Support Care Cancer · March 2, 2023 BACKGROUND: This study investigates whether high body mass index (BMI) in women diagnosed with early breast cancer (BC) is associated with patient-reported symptom severity during chemotherapy. METHODS: Women with Stage I-III BC completed toxicity reports ... Full text Link to item Cite

Abstract P6-05-51: Best Quality of Care from a Distance (BQual-D): Maintaining high quality care for hormone receptor positive (HR+) metastatic breast cancer (MBC) during the COVID pandemic, patient participation and satisfaction with the program

Conference Cancer Research · March 1, 2023 AbstractBackground During the COVID pandemic, we designed and implemented a program, called BQual-D, to maintain high quality care for patients with HR+, HER2 negative MBC who were taking oral anti-cancer th ... Full text Cite

Infrastructure to Support Accrual of Older Adults to National Cancer Institute Clinical Trials.

Journal Article J Natl Cancer Inst Monogr · December 15, 2022 As part of ongoing efforts to meaningfully improve recruitment, enrollment, and accrual of older adults into cancer clinical trials, the National Cancer Institute (NCI) sponsored a workshop with experts across the country entitled Engaging Older Adults in ... Full text Link to item Cite

Improving well-being for individuals with persistent pain after surgery for breast cancer, lobular carcinoma in situ, or ductal carcinoma in situ: A randomized clinical trial.

Journal Article Contemp Clin Trials · November 2022 >276,000 Americans will be diagnosed with invasive breast cancer, lobular carcinoma in situ, or ductal carcinoma in situ this year and most will undergo breast surgery as part of their care. Although prognosis is excellent, many patients experience persist ... Full text Link to item Cite

A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer.

Journal Article NPJ Breast Cancer · September 8, 2022 Identifying patients at higher risk of chemotherapy-induced peripheral neuropathy (CIPN) is a major unmet need given its high incidence, persistence, and detrimental effect on quality of life. We determined if the expression of p16, a biomarker of aging an ... Full text Link to item Cite

A Novel Staging System for De Novo Metastatic Breast Cancer Refines Prognostic Estimates.

Journal Article Ann Surg · April 1, 2022 OBJECTIVE: We aim to identify prognostic groups within a de novo metastatic cohort, incorporating both anatomic and biologic factors. BACKGROUND: Staging for breast cancer now includes anatomic and biologic factors, although the guidelines for stage IV dis ... Full text Link to item Cite

The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer.

Journal Article Clin Cancer Res · April 1, 2022 PURPOSE: HER2 mutations (HER2mut) induce endocrine resistance in estrogen receptor-positive (ER+) breast cancer. PATIENTS AND METHODS: In this single-arm multi-cohort phase II trial, we evaluated the efficacy of neratinib plus fulvestrant in patients with ... Full text Link to item Cite

Abstract P4-10-06: Best quality care from a distance (BQual-D): Maintaining high quality care for hormone receptor positive (HR+) metastatic breast cancer (MBC) during the COVID pandemic, description of the program and provider satisfaction

Conference Cancer Research · February 15, 2022 AbstractBackground: During the COVID pandemic, we designed and implemented a program, called BQual-D, to maintain high quality care for patients with HR+, HER2 negative MBC who were taking oral anti-cancer t ... Full text Cite

Patient-reported treatment toxicity and adverse events in Black and White women receiving chemotherapy for early breast cancer.

Journal Article Breast Cancer Res Treat · January 2022 PURPOSE: It is not known whether chemotherapy-related symptom experiences differ between Black and White women with early breast cancer (Stage I-III) receiving current chemotherapy regimens and, in turn, influences dose delay, dose reduction, early treatme ... Full text Link to item Cite

DEVELOPMENT, FEASIBILITY, AND ACCEPTABILITY OF A BEHAVIORAL WEIGHT AND SYMPTOM MANAGEMENT INTERVENTION FOR BREAST CANCER SURVIVORS AND INTIMATE PARTNERS.

Journal Article J Cancer Rehabil · 2022 BACKGROUND: Weight gain is common for breast cancer survivors and associated with disease progression, recurrence, and mortality. Traditional behavioral programs fail to address symptoms (i.e., pain, fatigue, distress) experienced by breast cancer survivor ... Full text Open Access Link to item Cite

Hereditary Cancer Counseling and Germline Genetic Testing

Chapter · September 15, 2021 Screening for inherited predisposition to cancer and germline genetic testing are part of the standard of care for breast cancer management, with implications for immediate and survivorship management. The advent of multigene next-generation sequencing pan ... Full text Link to item Cite

Sexual and Reproductive Health Concerns

Chapter · September 15, 2021 This book provides a clinically useful resource for evaluation and management of the symptoms and issues that burden survivors of breast cancer. ... Link to item Cite

Abstract CT026: A phase II trial of neratinib (NER) or NER plus fulvestrant (FUL) (N+F) in HER2 mutant, non-amplified (HER2mut) metastatic breast cancer (MBC): Part II of MutHER

Conference Cancer Research · July 1, 2021 AbstractIntroduction: The irreversible pan-HER inhibitor NER showed modest single agent activity for HER2mut MBC in Part I of MutHER trial. In Part II, we hypothesized that (1) N+F would improve activity in ... Full text Cite

Survival among patients with untreated metastatic breast cancer.

Conference Journal of Clinical Oncology · May 20, 2021 1095 Background: Treatments for metastatic breast cancer (MBC) have significantly improved survival for patients who receive treatment, yet data describing the prognosis for untreated patients is lacking. Therefore, we sought to ... Full text Cite

Patient-reported symptom severity, interference with daily activities, and adverse events in older and younger women receiving chemotherapy for early breast cancer.

Journal Article Cancer · March 15, 2021 BACKGROUND: To the authors' knowledge, it is unknown whether patient-reported symptom severity and symptom interference with daily activities differ between younger (aged <65 years) and older (aged ≥65 years) women receiving similar chemotherapy regimens f ... Full text Link to item Cite

Older adult participation in cancer clinical trials: A systematic review of barriers and interventions.

Journal Article CA Cancer J Clin · January 2021 Cancer is a disease of aging and, as the world's population ages, the number of older persons with cancer is increasing and will make up a growing share of the oncology population in virtually every country. Despite this, older patients remain vastly under ... Full text Link to item Cite

Arthralgias

Chapter · January 1, 2021 Musculoskeletal and joint pain are common in women, especially in perimenopausal and aging women. In women diagnosed with breast cancer, cancer treatment can be associated with musculoskeletal symptoms, particularly arthralgia, or non-inflammatory joint pa ... Full text Cite

Preface

Book · January 1, 2021 Cite

Common Issues in Breast Cancer Survivors: A Practical Guide to Evaluation and Management

Book · January 1, 2021 This book provides a clinically useful resource for evaluation and management of the symptoms and issues that burden survivors of breast cancer. Improvements to breast cancer screening and treatment have resulted in more patients than ever before having be ... Full text Cite

Effects of Breast Cancer Adjuvant Chemotherapy Regimens on Expression of the Aging Biomarker, p16INK4a.

Journal Article JNCI Cancer Spectr · December 2020 BACKGROUND: Although chemotherapy saves lives, increasing evidence shows that chemotherapy accelerates aging. We previously demonstrated that mRNA expression of p16INK4a , a biomarker of senescence and molecular aging, increased early and dramatically afte ... Full text Link to item Cite

Factors associated with falls in older women with breast cancer: the use of a brief geriatric screening tool in clinic.

Journal Article Breast Cancer Res Treat · November 2020 PURPOSE: Unintentional falls and breast cancer are common among older women, but the associations between them are understudied. We aimed to identify factors associated with falls in older women with breast cancer. METHODS: We retrospectively reviewed clin ... Full text Link to item Cite

Surgical Management of the Axilla in Elderly Women With Node-Positive Breast Cancer.

Journal Article J Surg Res · October 2020 BACKGROUND: Elderly women with clinically node-positive (cN+) breast cancer (BC) often have comorbidities that limit life expectancy and complicate treatment. We sought to determine whether the number of lymph nodes (LNs) retrieved among older women with n ... Full text Link to item Cite

Overall health at diagnosis predicts the risk of complications within the first year after breast cancer diagnosis.

Journal Article Breast Cancer Res Treat · July 2020 PURPOSE: Breast cancer patients with overall poor health are at a greater risk of both complications during treatment and mortality from competing causes. We sought to determine the association of pre-existing comorbidities on treatment-related complicatio ... Full text Link to item Cite

Congruence of patient- and clinician-reported toxicity in women receiving chemotherapy for early breast cancer.

Journal Article Cancer · July 1, 2020 BACKGROUND: The National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events, collected alongside the clinician-reported Common Terminology Criteria for Adverse Events, enables comparisons of patient a ... Full text Open Access Link to item Cite

The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part I: Early-Stage Disease.

Journal Article Drugs Aging · May 2020 The median age for breast cancer diagnosis is 62 years, but a disproportionate number of patients are over the age of 75 years and the majority of those have hormone receptor-positive, human epidermal growth factor receptor-2 (HER2)-negative cancers. This ... Full text Link to item Cite

The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part II: Metastatic Disease.

Journal Article Drugs Aging · May 2020 Breast cancer is a disease of aging, and the incidence of breast cancer is projected to increase dramatically as the global population ages. The majority of breast cancers that occur in older adults are hormone-receptor positive, human epidermal growth fac ... Full text Link to item Cite

Improving health engagement and lifestyle management for breast cancer survivors with diabetes.

Journal Article Contemp Clin Trials · May 2020 Breast cancer survivors with type 2 diabetes are at high risk for cancer recurrence, serious health complications, more severe symptoms, psychological distress, and premature death relative to breast cancer survivors without diabetes. Maintaining glycemic ... Full text Open Access Link to item Cite

Decreasing incidence of upper age restriction enrollment criteria among cancer clinical trials.

Journal Article J Geriatr Oncol · April 2020 BACKGROUND: Age disparities among cancer clinical trial participants are pervasive and worsening over time. Identification of factors associated with age disparities is critical to improve enrollment of older patients on trials. The incidence and impact of ... Full text Link to item Cite

Breast cancer and aging: Standing on the shoulders of a giant.

Journal Article J Geriatr Oncol · March 2020 With the aging of the US population, the number of individuals age 65 or older who will be diagnosed with breast cancer is expected to rise. Despite this, older adults with breast cancer remain severely under-represented in cancer clinical trials. Numerous ... Full text Link to item Cite

Patient-reported outcomes in the Translational Breast Cancer Research Consortium.

Journal Article Cancer · March 1, 2020 Members of the Translational Breast Cancer Research Consortium conducted an expert-driven literature review to identify a list of domains and to evaluate potential measures of these domains for inclusion in a list of preferred measures. Measures were inclu ... Full text Link to item Cite

Abstract P3-08-10: Characterization of oncotype DX recurrence score and chemotherapy utilization patterns in young women (≤40) with early stage ER+/HER-, lymph node negative breast cancer

Conference Cancer Research · February 15, 2020 AbstractBackground: Meta-analyses have demonstrated that young women ≤40 (YW) derive the most benefit from chemotherapy (EBCTCG, Lancet. 1998). Oncotype DX was designed to determine the benefit of chemothera ... Full text Cite

Abstract P5-14-17: Musculoskeletal side effects over time and association with adherence in women taking neoadjuvant letrozole for estrogen receptor positive DCIS: CALGB 40903 (Alliance)

Conference Cancer Research · February 15, 2020 AbstractBackground: Side effects of and adherence to aromatase inhibitors in women with ductal carcinoma in situ are not well described. Methods: Postmenopausal women in a prospective phase II study of neoad ... Full text Cite

A feasible and acceptable multicultural psychosocial intervention targeting symptom management in the context of advanced breast cancer.

Journal Article Psychooncology · February 2020 OBJECTIVE: Advanced breast cancer patients around the world experience high symptom burden (ie, distress, pain, and fatigue) and are in need of psychosocial interventions that target symptom management. This study examined the feasibility, acceptability, a ... Full text Link to item Cite

Investigating confounders of the association between survival and adjuvant radiation therapy after breast conserving surgery in a sample of elderly breast Cancer patients in Appalachia.

Journal Article BMC Cancer · December 17, 2019 BACKGROUND: To explain the association between adjuvant radiation therapy after breast conserving surgery (BCS RT) and overall survival (OS) by quantifying bias due to confounding in a sample of elderly breast cancer beneficiaries in a multi-state region o ... Full text Link to item Cite

Detecting geriatric needs in older patients with breast cancer through use of a brief geriatric screening tool.

Journal Article J Geriatr Oncol · November 2019 INTRODUCTION: Identification of geriatric syndromes is important for determining functional age and optimizing care for people with cancer. Based on administration of a geriatric screening tool, we aimed to describe needed resources for geriatric syndromes ... Full text Link to item Cite

Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practice.

Journal Article Cancer · September 1, 2019 BACKGROUND: In the current study, the authors investigated the incidence of moderate to severe chemotherapy-induced peripheral neuropathy (CIPN) for chemotherapy regimens commonly used in current clinical practice for the treatment of patients with early b ... Full text Link to item Cite

Partner status moderates the relationships between sexual problems and self-efficacy for managing sexual problems and psychosocial quality-of-life for postmenopausal breast cancer survivors taking adjuvant endocrine therapy.

Journal Article Menopause · August 2019 OBJECTIVE: Past studies indicate that >90% of breast cancer survivors taking adjuvant endocrine therapy (AET) experience menopausal symptoms including sexual problems (eg, vaginal dryness, dyspareunia); however, research examining the impact of these probl ... Full text Link to item Cite

A behavioral cancer pain intervention: A randomized noninferiority trial comparing in-person with videoconference delivery.

Journal Article Psychooncology · August 2019 OBJECTIVE: Behavioral cancer pain interventions are efficacious for improving important pain outcomes; yet, traditional in-person delivery limits patient access. This study compared videoconference-delivered mobile health pain coping skills training (mPCST ... Full text Link to item Cite

Cardiotoxicities of Modern Treatments in Breast Cancer.

Journal Article Curr Treat Options Cardiovasc Med · June 15, 2019 PURPOSE OF REVIEW: This paper will focus on novel breast cancer therapies used in clinical practice today, as well as review our understanding of standard therapies and their potential impact on cardiovascular health. RECENT FINDINGS: Established and novel ... Full text Link to item Cite

Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer.

Journal Article Oncologist · June 2019 BACKGROUND: This study explores the incidence of patient-reported major toxicity-symptoms rated "moderate," "severe," or "very severe"-for chemotherapy regimens commonly used in early breast cancer. PATIENTS AND METHODS: Female patients aged 21 years or ol ... Full text Link to item Cite

Risk of Cardiomyopathy in Breast Cancer: How Can We Attenuate the Risk of Heart Failure from Anthracyclines and Anti-HER2 Therapies?

Journal Article Curr Treat Options Cardiovasc Med · May 31, 2019 PURPOSE OF REVIEW: To review cardiotoxicity of and strategies to prevent cardiotoxicity from anthracyclines and anti-HER2 agents used to treat breast cancer. RECENT FINDINGS: Although not common, cardiotoxicity from anthracyclines and anti-HER2 therapies i ... Full text Link to item Cite

Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer.

Journal Article J Am Geriatr Soc · May 2019 OBJECTIVES: To analyze self-reported changes in physical function in older women with breast cancer receiving adjuvant chemotherapy. DESIGN: Secondary analysis of the Cancer and Leukemia Group B (CALGB) 49907 prospective randomized clinical trial. SETTING: ... Full text Link to item Cite

Age and the Risk of Paclitaxel-Induced Neuropathy in Women with Early-Stage Breast Cancer (Alliance A151411): Results from 1,881 Patients from Cancer and Leukemia Group B (CALGB) 40101.

Journal Article Oncologist · May 2019 PURPOSE: A few previous studies report a direct relationship between older age and chemotherapy-induced neuropathy. This study further evaluated this adverse event's age-based risk. METHODS: CALGB 40101 investigated adjuvant paclitaxel (80 mg/m2 once per w ... Full text Link to item Cite

Higher symptom burden is associated with lower function in women taking adjuvant endocrine therapy for breast cancer.

Journal Article J Geriatr Oncol · March 2019 OBJECTIVE: To explore the impact of symptoms on physical function in women on adjuvant endocrine therapy for breast cancer. METHODS: Eligible women were postmenopausal, had hormone receptor positive, stage I-IIIA breast cancer, completed surgery, chemother ... Full text Open Access Link to item Cite

Abstract P3-08-07: Distinct biological signatures describe differences in BRCA mutated subgroups

Conference Cancer Research · February 15, 2019 AbstractBackground: BRCA mutated (BRCA+) breast cancers are expected to have increased activation of Homologous Recombination Deficiency (HRD) and altered DNA damage repair pathways when compared to BRCA wil ... Full text Cite

Using a geriatric oncology assessment to link with services (GOAL).

Journal Article J Geriatr Oncol · January 2019 OBJECTIVE: Geriatric screening tools assess functional limitations and inform clinical decision-making for older adults with cancer. Our objective was to evaluate the feasibility and effectiveness of a screener in community-based oncology clinics. MATERIAL ... Full text Open Access Link to item Cite

What Do Breast Cancer Survivors Expect From Exercise?

Journal Article Cancer Nurs · 2019 BACKGROUND: Exercise outcome expectations (OEs) (ie, what one expects to obtain or avoid by exercising) are influential to increase exercise among cancer survivors. OBJECTIVE: The aim of this study was to measure the accessibility (ie, frequency one thinks ... Full text Link to item Cite

Testing a behavioral intervention to improve adherence to adjuvant endocrine therapy (AET).

Journal Article Contemp Clin Trials · January 2019 Adjuvant endocrine therapy (AET) is used to prevent recurrence and reduce mortality for women with hormone receptor positive breast cancer. Poor adherence to AET is a significant problem and contributes to increased medical costs and mortality. A variety o ... Full text Open Access Link to item Cite

Obesity and mortality after locoregional breast cancer diagnosis.

Journal Article Breast Cancer Res Treat · December 2018 PURPOSE: Higher mortality after a breast cancer diagnosis has been observed among women who are obese. We investigated the relationships between body mass index (BMI) and all-cause or breast cancer-specific mortality after a diagnosis of locoregional breas ... Full text Link to item Cite

Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype.

Journal Article Clin Breast Cancer · October 2018 BACKGROUND: Stromal tumor-infiltrating lymphocytes (TILs) might predict pathologic complete response (pCR) in patients with HER2-positive (HER2+) breast cancer treated with trastuzumab (H). Docetaxel (T), carboplatin (C), H, and pertuzumab (P) have immune- ... Full text Link to item Cite

A randomized phase II trial of MOVING ON: An intervention to increase exercise outcome expectations among breast cancer survivors.

Journal Article Psychooncology · October 2018 OBJECTIVE: The objective of the study is to test theoretical intervention fidelity and feasibility of MOVING ON, a self-directed, home-based, randomized controlled trial to increase exercise outcome expectations (OEs) (what one expects to obtain or avoid a ... Full text Link to item Cite

Immune profiling of BRCA-mutated breast cancers.

Conference Journal of Clinical Oncology · May 20, 2018 Full text Cite

Restaging de novo metastatic breast cancer to refine prognostic estimates.

Conference Journal of Clinical Oncology · May 20, 2018 Full text Cite

Risk of cancer death by comorbidity severity and use of adjuvant chemotherapy among women with locoregional breast cancer.

Journal Article J Geriatr Oncol · May 2018 OBJECTIVES: To examine the associations of comorbidity and chemotherapy with breast cancer- and non-breast cancer-related death. MATERIALS AND METHODS: Included were women with invasive locoregional breast cancer diagnosed in 2004 from seven population-bas ... Full text Link to item Cite

Androgen deprivation therapy (ADT) and cardiovascular mortality (CVD) in men with early-stage prostate cancer (PC) receiving curative radiation therapy (RT).

Conference Journal of Clinical Oncology · March 1, 2018 127 Background: Combined with RT, ADT is a highly effective and utilized treatment for men with localized PC, but some studies suggest that use of ADT leads to increased CVD. We explored the association between ADT and CVD in men ... Full text Cite

Protocol for Moving On: a randomized controlled trial to increase outcome expectations and exercise among breast cancer survivors.

Journal Article Nurs Open · January 2018 AIM: The aim of this study was to test the feasibility and fidelity of an intervention, Moving On, aimed to increase outcome expectations OEs (i.e. what one expects to obtain or avoid as a result of a behaviour) and exercise among breast cancer survivors. ... Full text Link to item Cite

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.

Journal Article Lancet Oncol · December 2017 BACKGROUND: ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, significantly improves 2-year invasive disease-free survival after trastuzumab-based adjuvant therapy in women with HER2-positive breast cancer. We repo ... Full text Link to item Cite

Personality, coping, and social support as predictors of long-term quality-of-life trajectories in older breast cancer survivors: CALGB protocol 369901 (Alliance).

Journal Article Psychooncology · November 2017 BACKGROUND: To determine long-term quality-of-life (QOL) trajectories among breast cancer survivors aged 65+ (older) evaluating the effects of personality and social support. METHODS: Older women (N = 1280) newly examined with invasive, nonmetastatic breas ... Full text Link to item Cite

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.

Journal Article Clin Cancer Res · October 1, 2017 Purpose: Based on promising preclinical data, we conducted a single-arm phase II trial to assess the clinical benefit rate (CBR) of neratinib, defined as complete/partial response (CR/PR) or stable disease (SD) ≥24 weeks, in HER2mut nonamplified metastatic ... Full text Link to item Cite

Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance).

Journal Article Breast Cancer Res Treat · July 2017 PURPOSE: Breast cancer patients aged 65+ ("older") vary in frailty status. We tested whether a deficits accumulation frailty index predicted long-term mortality. METHODS: Older patients (n = 1280) with non-metastatic, invasive breast cancer were recruited ... Full text Link to item Cite

Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503).

Journal Article Breast Cancer Res Treat · June 2017 PURPOSE: Tools to estimate survival, such as ePrognosis ( http://eprognosis.ucsf.edu/carey2.php ), were developed for general, not cancer, populations. In older patients with breast cancer, accurate overall survival estimates would facilitate discussions a ... Full text Link to item Cite

Optimizing delivery of a behavioral pain intervention in cancer patients using a sequential multiple assignment randomized trial SMART.

Journal Article Contemp Clin Trials · June 2017 BACKGROUND/AIMS: Pain is common in cancer patients and results in lower quality of life, depression, poor physical functioning, financial difficulty, and decreased survival time. Behavioral pain interventions are effective and nonpharmacologic. Traditional ... Full text Link to item Cite

Testing a behavioral intervention to improve adherence to adjuvant endocrine therapy (AET).

Conference Journal of Clinical Oncology · May 20, 2017 TPS10128 Background: Adjuvant endocrine therapy (AET) is a crucial component of treatment used to prevent recurrence and reduce mortality for women with hormone receptor positive breast cancer. Poor adherence to AET is a signific ... Full text Cite

Feasibility intervention to increase exercise outcome expectations among breast cancer survivors.

Conference Journal of Clinical Oncology · May 20, 2017 e21584 Background: Exercise is associated with decreased mortality and recurrence risk and improved quality of life for breast cancer survivors (BCS). Roughly 1/3 of BCS exercise enough to experience these benefits. A promising s ... Full text Cite

Cardio-oncology: The clinical overlap of cancer and heart disease

Book · April 11, 2017 Co-edited and written by an interdisciplinary team of experts in oncology and cardiology, this book is a clinically useful resource on these overlapping topics: Cardiac complications in patients receiving cancer therapy. The treatment of cancer in patients ... Full text Cite

Abstract P2-04-19: Elucidating the tumor immune microenvironment phenotype in early stage untreated BRCA mutated breast cancer patients

Conference Cancer Research · February 15, 2017 AbstractBackground: Increased stromal tumor infiltrating lymphocytes (TILs) are predictive and prognostic for improved outcomes from neoadjuvant or adjuvant chemotherapy in triple negative breast cancer. Inc ... Full text Cite

Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527.

Journal Article J Clin Oncol · February 2017 Purpose Despite increasing awareness of accrual challenges, it is unknown if accrual of older patients to breast cancer treatment trials is improving. Methods We examined accrual of older patients to Alliance for Clinical Trials in Oncology systemic therap ... Full text Link to item Cite

Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511).

Journal Article Breast Cancer Res Treat · January 2017 PURPOSE: We examined acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) events among 9679 women treated for breast cancer on four adjuvant Alliance for Clinical Trials in Oncology trials with >90 months of follow-up in order to better characte ... Full text Link to item Cite

Chemotherapy-related cognitive impairment in older patients with cancer.

Journal Article J Geriatr Oncol · July 2016 Chemotherapy-related cognitive impairment (CRCI) can occur during or after chemotherapy and represents a concern for many patients with cancer. Among older patients with cancer, in whom there is little clinical trial evidence examining side effects like CR ... Full text Link to item Cite

Understanding cognition in older patients with cancer.

Journal Article J Geriatr Oncol · July 2016 Cancer and neurocognitive disorders, such as dementia and delirium, are common and serious diseases in the elderly that are accompanied by high degree of morbidity and mortality. Furthermore, evidence supports the under-diagnosis of both dementia and delir ... Full text Link to item Cite

Breast cancer

Chapter · April 19, 2016 Cite

What Predicts an Advanced-Stage Diagnosis of Breast Cancer? Sorting Out the Influence of Method of Detection, Access to Care, and Biologic Factors.

Journal Article Cancer Epidemiol Biomarkers Prev · April 2016 BACKGROUND: Multiple studies have yielded important findings regarding the determinants of an advanced-stage diagnosis of breast cancer. We seek to advance this line of inquiry through a broadened conceptual framework and accompanying statistical modeling ... Full text Link to item Cite

Abstract P6-04-11: The foundation one assay influences clinical decision making in metastatic breast cancer

Conference Cancer Research · February 15, 2016 AbstractBackground:Tumor DNA sequencing is now readily available in metastatic breast cancer (MBC). The purpose of this study was to determine the effect of molecular testing ... Full text Cite

A Small Randomized Controlled Pilot Trial Comparing Mobile and Traditional Pain Coping Skills Training Protocols for Cancer Patients with Pain.

Journal Article Pain Res Treat · 2016 Psychosocial pain management interventions are efficacious for cancer pain but are underutilized. Recent advances in mobile health (mHealth) technologies provide new opportunities to decrease barriers to access psychosocial pain management interventions. T ... Full text Link to item Cite

Impact of comorbidity on cancer screening and diagnosis

Chapter · January 1, 2016 The presence of coexistent chronic disease or comorbid illness has been shown to have an impact on the pathogenesis of cancer and on the frequency of screening, the stage at diagnosis, the intensity of treatment, and, therefore, on cancer outcomes. This ch ... Full text Cite

Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy.

Journal Article Breast · October 2015 PURPOSE: To explore how symptoms and psychosocial factors are related to intentional and unintentional non-adherent medication taking behaviors. METHODS: Included were postmenopausal women with hormone receptor positive, stage I-IIIA breast cancer, who had ... Full text Open Access Link to item Cite

CHAMBER: A Regional Performance Improvement CME Initiative for Breast Cancer Health Care Providers.

Journal Article J Natl Compr Canc Netw · August 2015 CHAMBER was a regional educational initiative for providers of care to patients with HER2+ breast cancer. The study goals were to (1) enhance testing for HER2/neu overexpression in patients with invasive breast cancer; (2) increase the appropriate use of t ... Full text Link to item Cite

Adherence to adjuvant endocrine therapy for breast cancer: importance in women with low income.

Journal Article J Womens Health (Larchmt) · May 2015 There are wide disparities in breast cancer-specific survival by patient sociodemographic characteristics. Women of lower income, for instance, have higher relapse and death rates from breast cancer. One possible contributing factor for this disparity is l ... Full text Open Access Link to item Cite

Detecting geriatric needs in older breast cancer patients through use of a brief screener

Conference JOURNAL OF THE AMERICAN GERIATRICS SOCIETY · April 1, 2015 Link to item Cite

Patterns of locoregional treatment for nonmetastatic breast cancer by patient and health system factors.

Journal Article Cancer · March 1, 2015 BACKGROUND: The purpose of this study was to examine local definitive therapy for nonmetastatic breast cancer with the Patterns of Care Breast and Prostate Cancer (POCBP) study of the National Program of Cancer Registries (Centers for Disease Control and P ... Full text Link to item Cite

Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations†.

Journal Article Ann Oncol · February 2015 BACKGROUND: Screening tools are proposed to identify those older cancer patients in need of geriatric assessment (GA) and multidisciplinary approach. We aimed to update the International Society of Geriatric Oncology (SIOG) 2005 recommendations on the use ... Full text Link to item Cite

Individual, Area, and Provider Characteristics Associated With Care Received for Stages I to III Breast Cancer in a Multistate Region of Appalachia.

Journal Article J Oncol Pract · January 2015 PURPOSE: We describe individual, area, and provider characteristics associated with care patterns for early-stage breast cancer in Appalachian counties of Kentucky, North Carolina, Ohio, and Pennsylvania. METHODS: Cases of stages I to III breast cancer fro ... Full text Link to item Cite

A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007.

Journal Article Breast Cancer Res Treat · November 2014 Preclinical data suggest that medroxyprogesterone acetate (MPA) has both anti-metastatic and anti-angiogenic activity in the absence of hormone receptors (HR). This phase II trial assessed the activity of MPA alone or in combination with low-dose chemother ... Full text Link to item Cite

Patient experience and attitudes toward addressing the cost of breast cancer care.

Conference Oncologist · November 2014 BACKGROUND: The American Society of Clinical Oncology views patient-physician discussion of costs as a component of high-quality care. Few data exist on patients' views regarding how cost should be addressed in the clinic. METHODS: We distributed a self-ad ... Full text Link to item Cite

Self-efficacy for coping with symptoms moderates the relationship between physical symptoms and well-being in breast cancer survivors taking adjuvant endocrine therapy.

Journal Article Support Care Cancer · October 2014 PURPOSE: This study examined the relationships between physical symptoms, self-efficacy for coping with symptoms, and functional, emotional, and social well-being in women who were taking adjuvant endocrine therapy for breast cancer. METHODS: One hundred a ... Full text Link to item Cite

Obesity and guideline-concordant systemic therapy for locoregional breast cancer.

Journal Article J Clin Oncol · September 10, 2014 145 Background: Obese breast cancer patients tend to have higher mortality than non-obese patients. Hypothesizing that differences in receipt of adequate treatment may contribute to this mortality differential, we examined whether breast cancer patients wi ... Full text Link to item Cite

Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer on a clinical trial: CALGB 49907 and CALGB 361004 (alliance).

Journal Article J Oncol Pract · September 2014 PURPOSE: We evaluated associations among comorbidity, toxicity, time to relapse (TTR), and overall survival (OS) in older women with early-stage breast cancer receiving adjuvant chemotherapy. METHODS: Cancer and Leukemia Group B 49907 (Alliance) randomly a ... Full text Link to item Cite

Treatment patterns for prostate cancer: comparison of Medicare claims data to medical record review.

Journal Article Med Care · September 2014 BACKGROUND: As evidence-based guidelines increasingly define standards of care, the accurate reporting of patterns of treatment becomes critical to determine if appropriate care has been provided. We explore the level of agreement between claims and record ... Full text Link to item Cite

Breast and ovarian cancer in the older woman.

Journal Article J Clin Oncol · August 20, 2014 Nearly half of all women diagnosed with breast or ovarian cancer are age 65 years or older with the number of women diagnosed expected to increase as the population ages and life expectancy improves. Older women are less likely to be offered standard cance ... Full text Link to item Cite

Breast and ovarian cancer in the older woman.

Journal Article J Clin Oncol · August 20, 2014 Nearly half of all women diagnosed with breast or ovarian cancer are age 65 years or older with the number of women diagnosed expected to increase as the population ages and life expectancy improves. Older women are less likely to be offered standard cance ... Link to item Cite

Daughters and Mothers Against Breast Cancer (DAMES): main outcomes of a randomized controlled trial of weight loss in overweight mothers with breast cancer and their overweight daughters.

Journal Article Cancer · August 15, 2014 BACKGROUND: Few studies to date have used the cancer diagnosis as a teachable moment to promote healthy behavior changes in survivors of cancer and their family members. Given the role of obesity in the primary and tertiary prevention of breast cancer, the ... Full text Link to item Cite

Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901.

Journal Article J Clin Oncol · August 1, 2014 PURPOSE: Most patients with breast cancer age ≥ 65 years (ie, older patients) are eligible for adjuvant hormonal therapy, but use is not universal. We examined the influence of frailty on hormonal therapy noninitiation and discontinuation. PATIENTS AND MET ... Full text Link to item Cite

Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).

Journal Article J Clin Oncol · August 1, 2014 PURPOSE: Optimal adjuvant chemotherapy for early-stage breast cancer balances efficacy and toxicity. We sought to determine whether single-agent paclitaxel (T) was inferior to doxorubicin and cyclophosphamide (AC), when each was administered for four or si ... Full text Link to item Cite

The influence of diabetes severity on receipt of guideline-concordant treatment for breast cancer.

Journal Article Breast Cancer Res Treat · July 2014 Diabetes severity may influence breast cancer treatment choices. We examined whether receipt of guideline-concordant breast cancer treatment varied with diabetes severity. Cancer registry data from seven states regarding 6,912 stage I-III breast cancers we ... Full text Link to item Cite

Breast cancer and aging: results of the U13 conference breast cancer panel.

Journal Article Breast Cancer Res Treat · July 2014 Breast cancer is predominantly a disease of older women, yet there is a knowledge gap due to the persisting misalignment between the age distribution of women with breast cancer and the age distribution of participants in clinical trials. The purpose of th ... Full text Link to item Cite

Breast cancer screening, area deprivation, and later-stage breast cancer in Appalachia: does geography matter?

Journal Article Health Serv Res · April 2014 OBJECTIVE: To model the relationship of an area-based measure of a breast cancer screening and geographic area deprivation on the incidence of later stage breast cancer (LSBC) across a diverse region of Appalachia. DATA SOURCE: Central cancer registry data ... Full text Link to item Cite

Comorbidity burden and guideline-concordant care for breast cancer.

Journal Article J Am Geriatr Soc · March 2014 OBJECTIVES: To explore the relationship between level and type of comorbidity and guideline-concordant care for early-stage breast cancer. DESIGN: Cross-sectional. SETTING: National Program of Cancer Registry (NPCR) Breast and Prostate Cancer Patterns of C ... Full text Link to item Cite

Safety and efficacy of aerobic training in operable breast cancer patients receiving neoadjuvant chemotherapy: a phase II randomized trial.

Journal Article Acta Oncol · January 2014 BACKGROUND: To evaluate the safety and efficacy of moderate-to-high intensity aerobic training in breast cancer patients receiving neoadjuvant chemotherapy. METHODS: Twenty patients with stage IIB-IIIC operable breast cancer were randomly assigned to recei ... Full text Link to item Cite

Abstract S4-03: Exome sequencing reveals clinically actionable mutations in the pathogenesis and metastasis of triple negative breast cancer

Conference Cancer Research · December 15, 2013 AbstractTriple negative breast cancer (TNBC) represents a particularly aggressive and difficult to treat form of breast cancer. No specific genetic alterations have been described as characteristic of the di ... Full text Cite

Abstract P2-16-13: Phase I dose escalation clinical trial of the PI3K inhibitor BKM120 and capecitabine (C) in metastatic breast cancer (MBC)

Conference Cancer Research · December 15, 2013 AbstractBackground: PIK3CA is one of the most frequently mutated genes in human breast cancer, and the high expression of a PIK3CA-pathway signature is associated with the poor prognosis Luminal B and Basal- ... Full text Cite

Abstract P1-09-05: Does socioeconomic status (SES) influence receipt of guideline concordant care in older women with breast cancer: Findings from a Centers for Disease Control and Prevention national program of cancer registries (NPCR) patterns of care study

Conference Cancer Research · December 15, 2013 AbstractBackground: Lower SES is associated with worse breast cancer outcomes in general. Disparities by SES have not been well studied in older cancer patients. Here, we examined differences in presentation ... Full text Cite

Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer.

Journal Article Clin Breast Cancer · December 2013 BACKGROUND: Triple negative metastatic breast cancer can be difficult to treat with primarily cytotoxic options. Nab-paclitaxel has demonstrated improved PFS and tolerability compared with standard cremophor-solubilized paclitaxel; based on this, we examin ... Full text Link to item Cite

A planned, prospective comparison of short-term quality of life outcomes among older patients with breast cancer treated with standard chemotherapy in a randomized clinical trial vs. an observational study: CALGB #49907 and #369901.

Journal Article J Geriatr Oncol · October 2013 OBJECTIVES: Patients ≥ 65 years old ("older") are often not included in randomized clinical trials (RCT), but when they are, care in an RCT might improve quality of life (QoL). We conducted a prospective comparison of QoL among older women receiving standa ... Full text Link to item Cite

Patient experiences and preferences for survivorship care.

Journal Article J Clin Oncol · September 10, 2013 110 Background: The optimal method for delivery of care to over 2 million breast cancer survivors in the U.S. remains unclear, with multiple models currently in practice. This study involved a patient-centered investigation of experiences and preferences f ... Full text Link to item Cite

Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy.

Journal Article Cancer Prev Res (Phila) · September 2013 Aerobic exercise training (AET) is an effective adjunct therapy to attenuate the adverse side-effects of adjuvant chemotherapy in women with early breast cancer. Whether AET interacts with the antitumor efficacy of chemotherapy has received scant attention ... Full text Link to item Cite

Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907.

Journal Article Breast Cancer Res Treat · June 2013 Cognitive changes in older women receiving chemotherapy are poorly understood. We examined self-reported cognitive function for older women who received adjuvant chemotherapy on Cancer and Leukemia Group B (CALGB) 49907. CALGB 49907 randomized 633 women ag ... Full text Link to item Cite

Predictors of care for early-stage breast cancer in Appalachia

Conference JOURNAL OF CLINICAL ONCOLOGY · May 20, 2013 Link to item Cite

Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women.

Journal Article Am J Clin Oncol · April 2013 OBJECTIVES: Although clinical trials have demonstrated the benefit of adjuvant hormonal therapy for hormone receptor-positive breast cancer, it is not known whether poor medication adherence might impact outcomes, particularly in the context of a low-incom ... Full text Link to item Cite

Multidisciplinary care of patients with early-stage breast cancer.

Journal Article Surg Oncol Clin N Am · April 2013 There is a compelling need for close coordination and integration of multiple specialties in the management of patients with early-stage breast cancer. Optimal patient care and outcomes depend on the sequential and often simultaneous participation and dial ... Full text Link to item Cite

Symptom communication in breast cancer: relationships of holding back and self-efficacy for communication to symptoms and adjustment.

Journal Article J Psychosoc Oncol · 2013 Adjuvant endocrine therapy improves overall survival for women with breast cancer. However, side effects may compromise patients' quality of life (QOL). This study examined how two communication variables (self-efficacy for symptom communication [SE] and h ... Full text Link to item Cite

Abstract P6-08-05: Changes in Cognitive Function in Older Women With Breast Cancer Treated with Standard Chemotherapy and Capecitabine within CALGB 49907

Conference Cancer Research · December 15, 2012 AbstractBackground: Cognitive changes for older women who receive chemotherapy are poorly understood.Methods: Cancer and Leukemia Group B (CALGB) 49907 enrolled 633 women ≥65 ... Full text Cite

Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.

Journal Article J Clin Oncol · November 20, 2012 PURPOSE: The ideal duration of adjuvant chemotherapy for patients with lower risk primary breast cancer is not known. Cancer and Leukemia Group B trial 40101 was conducted using a phase III factorial design to define whether six cycles of a chemotherapy re ... Full text Link to item Cite

Defining care provided for breast cancer based on medical record review or Medicare claims: information from the Centers for Disease Control and Prevention Patterns of Care Study.

Journal Article Ann Epidemiol · November 2012 BACKGROUND: Description of care patterns is important as evidence-based guidelines increasingly dictate care. We explore the level of agreement between claims and record abstraction for guideline concordant multidisciplinary breast cancer care. METHODS: Fr ... Full text Link to item Cite

(AI) Can't get off my chair.

Journal Article J Am Geriatr Soc · October 2012 Full text Link to item Cite

Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer.

Journal Article Breast Cancer Res Treat · July 2012 Capecitabine is often offered as a first-line chemotherapy option for metastatic breast cancer (MBC). In this study, we compare characteristics of and survival among women prescribed first-line capecitabine or taxane monotherapy for MBC. Women receiving fi ... Full text Link to item Cite

A randomized trial of exercise on well-being and function following breast cancer surgery: the RESTORE trial.

Journal Article J Cancer Surviv · June 2012 OBJECTIVES: This study aimed to determine the effect of a moderate, tailored exercise program on health-related quality of life, physical function, and arm volume in women receiving treatment for nonmetastatic breast cancer. METHODS: Women who were within ... Full text Link to item Cite

Adjuvant Radiation and Outcomes After Breast Conserving Surgery in Publicly Insured Patients.

Journal Article J Geriatr Oncol · April 1, 2012 OBJECTIVES: Epidemiologic studies report that lack of adjuvant radiation (RT) after breast conserving surgery (BCS) is associated with higher short-term mortality. It is generally accepted that adjuvant RT decreases risk of breast cancer recurrence and the ... Full text Link to item Cite

Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers.

Journal Article J Clin Oncol · January 10, 2012 PURPOSE: For breast cancer, guidelines direct the delivery of adjuvant systemic therapy on the basis of lymph node status, histology, tumor size, grade, and hormonal receptor status. We explored how race/ethnicity, insurance, census tract-level poverty and ... Full text Link to item Cite

P1-13-03: Zoledronic Acid Induces an Immune Response in Breast Cancer Patients through Stimulation of Central Memory and Effector Memory gamma/delta T-Cells.

Journal Article Cancer Research · December 15, 2011 AbstractBackground Zoledronic acid (ZA) in combination with endocrine therapy (ET) and ovarian ablation (OA) reported a DFS advantage in premenopausal women with early stage breast cancer (EBC) in ABCSG-12. ... Full text Cite

Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing.

Journal Article Clin Cancer Res · September 15, 2011 PURPOSE: A phase II study of dasatinib, an inhibitor of multiple oncogenic tyrosine kinases including Src, was conducted to evaluate 16-week progression-free rate and tolerability in patients with previously treated metastatic breast cancer (MBC). Real-tim ... Full text Link to item Cite

Adjuvant chemotherapy for breast cancer in older women: emerging evidence to aid in decision making.

Journal Article Curr Treat Options Oncol · September 2011 To prevent breast cancer-related recurrence and death, adjuvant therapy, including chemotherapy, is given. The decision to deliver chemotherapy requires careful weighing of the risk of toxicity versus the estimated benefit. The risk and benefit are based o ... Full text Link to item Cite

Developing a claim-based version of the ACE-27 comorbidity index: a comparison with medical record review.

Journal Article Med Care · August 2011 OBJECTIVES: The adult comorbidity evaluation (ACE-27) is a medical record-based comorbidity index that predicts survival among various types of cancer patients. The purpose of this study was to compare the medical record-based ACE-27 instrument to a newly ... Full text Link to item Cite

Symptom experiences and nonadherent medication-taking behaviors of breast cancer patients taking adjuvant hormone therapy.

Journal Article J Clin Oncol · May 20, 2011 524 Background: Many breast cancer patients do not adhere to prescribed adjuvant hormone therapy. This pilot study explored symptom experiences and medication adherence behaviors. METHODS: Eligible women were postmenopausal, had hormone receptor positive s ... Link to item Cite

Different risk factors for mortality in younger and older women after breast-conserving surgery.

Journal Article J Clin Oncol · May 20, 2011 6017 Background: We previously reported that death rates were higher among women who had breast conserving surgery (BCS) but no adjuvant radiation. Here, we investigate factors associated with overall survival after BCS in younger and older women. METHODS: ... Link to item Cite

Safety and efficacy of single-agent adjuvant trastzumab in older women with breast cancer.

Journal Article J Clin Oncol · May 20, 2011 TPS109 Background: Trastuzumab is a humanized monoclonal antibody targeting the extracellular domain of the human epidermal growth factor receptor 2 (HER2) protein. The addition of trastuzumab to adjuvant chemotherapy, either concomitant or sequential, lea ... Link to item Cite

Abstract 5024: Effects of aerobic training to improve cardiovascular function and prevent cardiac remodeling after cytotoxic therapy in early breast cancer

Conference Cancer Research · April 15, 2011 AbstractBackground: It is well-established that doxorubicin (DOX)-containing chemotherapy causes progressive cardiomyopathy clinically manifest as decreased left ventricular ejection fraction (LVEF). The eff ... Full text Cite

Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907.

Journal Article J Clin Oncol · March 10, 2011 PURPOSE: A phase III trial (Cancer and Leukemia Group B CALGB-49907) was conducted to test whether older patients with early-stage breast cancer would have equivalent relapse-free and overall survival with capecitabine compared with standard chemotherapy. ... Full text Link to item Cite

Cardiovascular complications of breast cancer therapy in older adults.

Journal Article Oncologist · 2011 Older adults frequently have pre-existing and cancer-related risk factors for cardiovascular toxicity from cancer treatment. In this review, we discuss the risk factors and strategies for prevention and management of cardiovascular complications in older w ... Full text Link to item Cite

Hot flashes in breast cancer survivors and an association with calcium supplement use

Journal Article International Journal of Women S Health · September 28, 2010 Aims: In breast cancer survivors, we aimed to describe the frequency of hot flashes and night sweats, frequency and type of treatment, and the association of hot flashes and use of calcium supplements. Methods: Charts of breast cancer survivors were review ... Full text Cite

Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer.

Journal Article J Natl Cancer Inst · July 7, 2010 BACKGROUND: Tamoxifen use has been associated with increased risk of thromboembolic events (TEs) in women with breast cancer and women at high risk for the disease. Factor V Leiden (FVL) is the most common inherited clotting factor mutation and also confer ... Full text Link to item Cite

Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physicians.

Journal Article J Clin Oncol · July 1, 2010 PURPOSE: Breast cancer chemotherapy decisions in patients > or = 65 years old (older) are complex because of comorbidity, toxicity, and limited data on patient preference. We examined relationships between preferences and chemotherapy use. METHODS: Older w ... Full text Link to item Cite

A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer.

Journal Article Breast Cancer Res Treat · February 2010 The purpose of this study was to determine the safety and maximum tolerated dose (MTD) of BZL101 (FDA IND# 59,521), an orally delivered aqueous extract from the herb Scutellaria barbata, in women with metastatic breast cancer (MBC). The trial was an open-l ... Full text Link to item Cite

Management of breast cancer in older adults

Journal Article · January 1, 2010 Introduction Increasing age is a major risk factor for the development of breast cancer. While approximately 1 in 233 women are diagnosed with breast cancer in the fourth decade of life, the risk increases to 1 in 27 in the seventh decade (Figure 7.1). Thu ... Full text Cite

Breast cancer patients' treatment expectations after exposure to the decision aid program adjuvant online: the influence of numeracy.

Journal Article Med Decis Making · 2010 The decision aid called ''Adjuvant Online'' (Adjuvant! for short) helps breast cancer patients make treatment decisions by providing numerical estimates of treatment efficacy (e.g., 10-y relapse or survival). Studies exploring how patients' numeracy intera ... Full text Link to item Cite

Patient and provider determinants associated with the prescription of adjuvant hormonal therapies following a diagnosis of breast cancer in Medicaid-enrolled patients.

Journal Article J Natl Med Assoc · November 2009 PURPOSE: This study examined patient and provider characteristics associated with being prescribed an aromatase inhibitor (AI) vs tamoxifen-only therapy among a cohort of postmenopausal North Carolina Medicaid enrollees diagnosed with hormone receptor-posi ... Full text Link to item Cite

Cost impact of oral capecitabine compared to intravenous taxane-based chemotherapy in first-line metastatic breast cancer.

Journal Article J Med Econ · September 2009 OBJECTIVE: Few studies have examined the costs associated with differing first-line chemotherapy regimens in patients with metastatic breast cancer (MBC). This study compares the relative cost impact of women starting first-line chemotherapy with capecitab ... Full text Link to item Cite

Adjuvant hormonal therapy use among insured, low-income women with breast cancer.

Journal Article J Clin Oncol · July 20, 2009 PURPOSE Use of adjuvant hormonal therapy, which significantly decreases breast cancer mortality, has not been well described among poor women, who are at higher risk of cancer-related death. Here we explore use of adjuvant hormonal therapy in an insured, l ... Full text Link to item Cite

Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis.

Journal Article J Clin Oncol · June 10, 2009 PURPOSE: Nonhormonal treatment options have been investigated as treatments for hot flashes, a major clinical problem in many women. Starting in 2000, a series of 10 individual double-blind placebo-controlled studies has evaluated newer antidepressants and ... Full text Link to item Cite

The relationship between adherence to adjuvant hormonal therapy and survival among low-income, insured women with primary breast cancer.

Journal Article J Clin Oncol · May 20, 2009 e11522 Background: Clinical trials and meta-analyses show that adjuvant hormonal therapy for hormone receptor positive breast cancer significantly decreases risk of death. We explored the relationship between adherence to adjuvant hormonal therapy and deat ... Link to item Cite

Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944).

Journal Article Breast Cancer Res Treat · February 2009 PURPOSE: To describe long-term results of a multimodality strategy for stage III breast cancer utilizing neoadjuvant doxorubicin followed by mastectomy, CMF, and radiotherapy. PATIENTS AND METHODS: Women with biopsy-proven, clinical stage III breast cancer ... Full text Link to item Cite

Health system correlates of receipt of radiation therapy after breast-conserving surgery: a study of low-income Medicaid-enrolled women.

Journal Article Am J Manag Care · October 2008 OBJECTIVE: To describe patient and healthcare system correlates of receipt of recommended care in North Carolina (NC) as indicated by receipt of adjuvant radiation therapy (RT) after breast-conserving surgery (BCS). STUDY DESIGN: Retrospective cohort study ... Link to item Cite

Geriatric oncology: past, present, future.

Journal Article J Oncol Pract · July 2008 Efforts to integrate geriatric oncology principles in the training of all medical oncologists are underway. ... Full text Link to item Cite

A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer.

Journal Article Cancer Invest · 2008 BACKGROUND: Premenopausal women treated for early stage breast cancer (ESBC) are at risk for chemotherapy-related amenorrhea (CRA). Prospectively-validated, predictive markers of CRA are needed. PATIENTS AND METHODS: Premenopausal women with ESBC and plann ... Full text Link to item Cite

BMI influences prognosis following surgery and adjuvant chemotherapy for lymph node positive breast cancer.

Journal Article Breast J · 2008 Increased body mass index (BMI) at diagnosis has been shown to be associated with an increased risk of disease recurrence and death. However, the association has not been consistent in the literature and may depend on several factors such as menopausal sta ... Full text Link to item Cite

Research on optimal recovery practices in breast cancer: the RESTORE trial

Conference BREAST CANCER RESEARCH AND TREATMENT · December 1, 2007 Link to item Cite

Cognitive-behavioral intervention for hot flashes.

Journal Article Oncol Nurs Forum · January 2007 PURPOSE/OBJECTIVES: To pilot test the acceptability of a DVD platform to deliver a newly created cognitive-behavioral hot flash intervention and estimate the efficacy of the new intervention. DESIGN: Nonrandomized pretest, post-test design. SETTING: Midwes ... Full text Link to item Cite

Survival disadvantage among Medicaid-insured breast cancer patients treated with breast conserving surgery without radiation therapy.

Journal Article Breast Cancer Res Treat · January 2007 BACKGROUND: Clinical studies indicate that breast cancer patients treated with breast conserving surgery (BCS) without radiotherapy (RT) have a greater risk of recurrence and mortality compared to those receiving BCS plus RT. However, this relationship has ... Full text Link to item Cite

The Witherby/Muss article reviewed

Journal Article Oncology · December 1, 2006 Cite

The Extermann article reviewed

Journal Article Oncology · December 1, 2006 Cite

Retrospective study of the effect of comorbidity on use of adjuvant chemotherapy in older women with breast cancer in a tertiary care setting.

Journal Article Crit Rev Oncol Hematol · September 2006 Use of adjuvant chemotherapy for breast cancer decreases with increasing age. We examined the effect of comorbidity on adjuvant chemotherapy use in older women (age >55 years) in a tertiary care Oncology Clinic. Clinic charts of new, early stage breast can ... Full text Link to item Cite

Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide.

Journal Article Clin Breast Cancer · August 2006 BACKGROUND: Adjuvant trastuzumab improves relapse-free survival in HER2-overexpressing breast cancer but is associated with cardiac toxicity. This phase II study was undertaken to determine the neoadjuvant clinical and pathologic response rate and the acut ... Full text Link to item Cite

Managing early-stage breast cancer in your older patients

Journal Article ONCOLOGY-NEW YORK · August 1, 2006 Link to item Cite

Relationship between numeracy and breast cancer patients' estimates of adjuvant treatment benefit.

Journal Article J Clin Oncol · June 20, 2006 586 Background: Based on clinical anecdotes and existing literature, the general population has trouble understanding and making use of statistical information. We explored the accuracy of breast cancer patients' (pts) estimates of treatment outcomes (prob ... Link to item Cite

Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen.

Journal Article Breast J · 2006 We observed the relief of hot flashes in breast cancer survivors taking tamoxifen and treated with sertraline for depression. Our objective was to assess the effect of sertraline on the frequency and severity of hot flashes, mood status, and health-related ... Full text Link to item Cite

In reply [10]

Journal Article Journal of Clinical Oncology · December 1, 2005 Full text Cite

Patterns of care among breast cancer patients with financial need: Information from a Medicaid-claims and tumor registry linked database.

Journal Article J Clin Oncol · June 2005 6037 Background: There is little information describing patterns of health care in financially needy women with breast cancer in the United States. METHODS: We previously created and validated a hybrid database linking Medicaid-claims and tumor registry da ... Link to item Cite

Improving accrual of older persons to cancer treatment trials: a randomized trial comparing an educational intervention with standard information: CALGB 360001.

Journal Article J Clin Oncol · April 1, 2005 PURPOSE: To design and test a geriatric educational intervention to improve accrual of cancer patients age 65 years and older to cooperative group-sponsored treatment trials. METHODS: Main member institutions of the Cancer and Leukemia Group B (CALGB) and ... Full text Link to item Cite

Breast cancer in older patients.

Journal Article Semin Oncol · April 2004 Breast cancer is a common problem and a major health concern in our growing geriatric population. Older breast cancer patients are at risk for less than standard management, the appropriateness of which is difficult to discern. Breast tumors tend to have l ... Full text Link to item Cite

Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041).

Journal Article Invest New Drugs · January 2004 New and more effective treatments are needed for metastatic breast cancer. This study aimed to determine the effectiveness of a combination of subcutaneously administered recombinant human interleukin-2 (rIL-2), 1.5 MU/m(2) for 5 consecutive days repeated ... Full text Link to item Cite

Long-term follow-up of a phase II trial studying a weekly doxorubicin-based multiple drug adjuvant therapy for stage II node-positive carcinoma of the breast.

Journal Article Breast Cancer Res Treat · April 2002 BACKGROUND: Combination chemotherapy improves outcomes in women with breast cancer (BC) that involves axillary nodes. This single-arm study aimed to evaluate the effectiveness of an intensive doxorubicin-based multidrug regimen as adjuvant therapy in women ... Full text Link to item Cite

Interpreting measures of treatment effect in cancer clinical trials.

Journal Article Oncologist · 2002 The efficacy of a new cancer regimen is usually assessed by analyzing outcomes such as tumor response and overall survival. Many publications summarizing results of cancer clinical trials report measures such as odds ratios and hazard ratios, as these are ... Full text Link to item Cite

Systemic therapy for older women with breast cancer.

Journal Article Oncology (Williston Park) · March 2001 Breast cancer is a common problem in older women. As the number of medical illnesses increases with age and the life expectancy decreases, the benefits of systemic therapy for women with breast cancer become questionable. All women over age 65 years are at ... Link to item Cite

Breast cancer and aging. Clinical interactions.

Journal Article Hematol Oncol Clin North Am · February 2000 The incidence and mortality rates of breast cancer increase with age. As the geriatric population grows, the number of breast cancer cases will reach epidemic proportions. The number of coexisting medical conditions also increases with advancing age. The p ... Full text Link to item Cite

Endocrine therapy in metastatic breast cancer.

Journal Article Cancer Treat Res · 1998 Endocrine therapy represents a mainstay of effective, minimally toxic, palliative treatment for metastatic breast cancer. Research focusing on the mechanism of action of endocrine agents will provide new insights leading to new hormonal approaches in breas ... Full text Link to item Cite

Quality-of-life measurement in women with breast cancer

Journal Article Breast Journal · August 12, 1997 The health-related quality of life (QOL) of breast cancer patients has been the focus of study for many years. However, it is only recently that the quality-of-life construct has been precisely defined and measured with validated, reliable instruments. The ... Full text Cite

Breast cancer in older women.

Journal Article Clin Geriatr Med · May 1997 More than 50% of breast cancers are diagnosed in women aged 65 years or older, a quickly growing segment of the population. Healthy older women should be offered state-of-the-art screening and treatment for breast cancer, including mammography, surgery, ra ... Link to item Cite

Cancer chemotherapy in older adults. A tolerability perspective.

Journal Article Drugs Aging · January 1997 The incidence of cancer increases with age. Since the geriatric population is growing, we will be confronted with an increasing number of patients with cancer who are > 65 years of age. The purpose of this review is to address the use of cancer chemotherap ... Full text Link to item Cite

Vitamin E and breast cancer: a review.

Journal Article Nutr Cancer · 1997 Breast cancer is a major health problem in America, accounting for almost one-third of cancer-related deaths in women. The prevention of breast cancer through dietary modification is an active area of clinical and epidemiologic research. It has been propos ... Full text Link to item Cite

Rhabdomyolysis and hemolysis associated with sickle cell trait and glucose-6-phosphate dehydrogenase deficiency.

Journal Article South Med J · November 1996 We report a case of severe oxidative hemolysis and rhabdomyolysis in a patient with sickle cell trait and glucose-6-phosphate dehydrogenase (G6PD) deficiency. The patient was a 34-year-old black man admitted 24 hours after vigorous exercise with myalgias, ... Full text Link to item Cite

Tamoxifen in postmenopausal women a safety perspective.

Journal Article Drugs Aging · May 1996 Tamoxifen is a synthetic antiestrogen with both agonist and antagonist properties. It is believed to act primarily through binding to estrogen receptors in breast cancer cells, acting as a competitive inhibitor of estrogen. Tamoxifen has a wide range of sy ... Full text Link to item Cite

Current status of endocrine therapy for metastatic breast cancer.

Journal Article Oncology (Williston Park) · September 1995 Hormonal manipulation is currently the mainstay of palliative care for metastatic breast cancer because it is well tolerated and produces significant responses in approximately one-third of unselected patients. Tamoxifen, a nonsteroidal antiestrogen, is cu ... Link to item Cite

Breast Cancer in Older Women

Journal Article Breast Journal · January 1, 1995 Abstract: This review addresses the management of breast cancer in women over 65 years of age. In 1995, approximately 50% of breast cancers will be diagnosed in this quickly growing segment of our population. Breast cancer screening and treatment modalitie ... Full text Cite

A comparison of treatment outcomes for black patients and white patients with metastatic breast cancer. The Piedmont Oncology Association experience.

Journal Article Cancer · June 1, 1991 Prior studies have shown that black patients with breast cancer have poorer survival times compared with white patients even when adjusted for stage. Seventy-four black patients treated on six Piedmont Oncology Association (POA) protocols were compared wit ... Full text Link to item Cite